Medibank Private is tracked as a listed Australian private health insurer and health-services group, headquartered in Australia. Medibank brings a private-health specialist model and June financial year, with insurer, health-services, regulatory, and cyber-event reporting that differs sharply from multi-line P&C and life groups.
Source-reviewed company references
Medibank Private: Medibank Private Issuer Record / exchange record
The exchange path supports the listed parent, code, and announcement chain.
Why it matters: This card anchors Medibank Private evidence from Medibank Private Issuer Record / exchange record and preserves the stated disclosure scope.
Public exchange path reviewed. Exclude current security price, volume, and performance.
Public exchange path reviewed. Exclude current security price, volume, and performance.
Medibank Private: 2025 Annual Report / annual report
Reported NPAT was AUD 500.8 million, underlying NPAT AUD 618.7 million, group operating profit AUD 762.4 million, health-insurance premium revenue AUD 8,211.0 million, and operating margin 9.0%.
Why it matters: This card anchors Medibank Private evidence from 2025 Annual Report / annual report and preserves the stated disclosure scope.
HTTP 200 official PDF reviewed. Underlying NPAT is non-GAAP and AASB 17 and cyber-event effects must remain explicit.
HTTP 200 official PDF reviewed. Underlying NPAT is non-GAAP and AASB 17 and cyber-event effects must remain explicit.
Medibank Private: FY2025 Results Library / full-year results
The library provides Appendix 4E, financial report, investor presentation, and media release for the June 2025 year.
Why it matters: This card anchors Medibank Private evidence from FY2025 Results Library / full-year results and preserves the stated disclosure scope.
HTTP 200 official page reviewed. Do not compare the June year-end directly with calendar-year peers without labels.
HTTP 200 official page reviewed. Do not compare the June year-end directly with calendar-year peers without labels.
Medibank Private: Private Health Insurance Statistics / regulatory context
APRA provides independent policyholder, premium, benefits, membership, and industry statistics used only when the exact quarter and denominator are stated.
Why it matters: This card anchors Medibank Private evidence from Private Health Insurance Statistics / regulatory context and preserves the stated disclosure scope.
HTTP 200 regulator page reviewed. Industry statistics are not automatically Medibank company metrics.
HTTP 200 regulator page reviewed. Industry statistics are not automatically Medibank company metrics.
Full company reference archive
View the complete source-reviewed company reference archive, including reporting periods, source dates, reviewed dates, methodology notes, reader cautions, and official source links.
Business And Entity Overview
Medibank's FY2025 report and results paths provide group and health-insurance measures; APRA and ASX paths supply independent regulated-industry and listed-company context. The profile is bounded to Medibank Private Limited and the consolidated or parent scope identified by each source. It does not transfer group figures automatically to every licensed insurer, branch, brand, or other subsidiary.
Source-Reviewed Evidence
- 2025 Annual Report / annual report (FY2025, year ended 2025-06-30). Reported NPAT was AUD 500.8 million, underlying NPAT AUD 618.7 million, group operating profit AUD 762.4 million, health-insurance premium revenue AUD 8,211.0 million, and operating margin 9.0%. Scope: Medibank Group and named Health Insurance and Medibank Health segments. Caution: HTTP 200 official PDF reviewed. Underlying NPAT is non-GAAP and AASB 17 and cyber-event effects must remain explicit.
- FY2025 Results Library / full-year results (FY2025 results announced 2025-08-28). The library provides Appendix 4E, financial report, investor presentation, and media release for the June 2025 year. Scope: Medibank Group and disclosed segments. Caution: HTTP 200 official page reviewed. Do not compare the June year-end directly with calendar-year peers without labels.
- Private Health Insurance Statistics / regulatory context (Quarterly regulatory series through the relevant FY2025 period). APRA provides independent policyholder, premium, benefits, membership, and industry statistics used only when the exact quarter and denominator are stated. Scope: Australian private health insurance industry and regulated insurers. Caution: HTTP 200 regulator page reviewed. Industry statistics are not automatically Medibank company metrics.
- Medibank Private Issuer Record / exchange record (Current issuer record reviewed 2026-07-15). The exchange path supports the listed parent, code, and announcement chain. Scope: Medibank Private Limited ASX code MPL. Caution: Public exchange path reviewed. Exclude current security price, volume, and performance.
Entity Boundary
Use Medibank Private Limited as the listed parent and group. Medibank and ahm health-insurance brands, Medibank Health services, and other subsidiaries or businesses remain separately scoped; APRA private-health-insurance statistics use their own regulated perimeter. The Australian June year-end differs from calendar-year companies. Keep Health Insurance and Medibank Health segment measures, AASB 17 effects, and cyber-event costs separate.
Lines And Geographic Context
The reviewed source pack supports connections to Life and Health. Australia is the home-jurisdiction reference; other geographies require their own segment or legal-entity support.
Why This Profile Exists
Keeping the 4 reviewed source cards together gives readers a stable route from corporate identity to periodic reporting, capital or regulatory context, and public listing or profile evidence. The profile does not present a score, comparison table, or commercial recommendation.
Reader Note
This profile is source-led reference material. Periodic figures retain the source's metric label, unit, reporting period, and entity scope. Ratings, regulatory measures, listing records, and issuer-defined measures are contextual evidence, not standalone judgments about financial strength, suitability, security value, product choice, pricing, or available insurance capacity.